3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Melanoma
32
Neoplasms
14
Carcinoma, Non-Small-Cell Lung
10
Colorectal Neoplasms
8
Ovarian Neoplasms
7
Multiple Myeloma
6
Breast Neoplasms
6
Pancreatic Neoplasms
5
Neoplasm Metastasis
4
Hematologic Neoplasms
4
Solid Tumors
3
Neoplasms by Site
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Gastrointestinal Neoplasms
3
Cholangiocarcinoma
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Solid Tumor
2
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Neoplasms by Histologic Type
2
Leukemia, Myelomonocytic, Chronic
2
Gallbladder Neoplasms
2
Fallopian Tube Neoplasms
2
Interventions
cobimetinib
2
trametinib
1
temsirolimus
1
dabrafenib
1
Vemurafenib
1
Valproic Acid
1
Specimen Handling
1
Sirolimus
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
Immunoglobulin G
1
Disulfides
1
Cetuximab
1
Biopsy
1
Bevacizumab
1
68Ga-pentixafor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Erdheim-Chester Disease
×
cobimetinib
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT04079179
2025-09-18
NACHO-COBI
Baylor College of Medicine
Phase 2
Recruiting
90 enrolled